Early detection of toxic events induced by drug cantidats is mandatory in order to avoid late attrition in the process of R&D. Steatosis is an accumulation of triglicerids within the liver cells and may lead steatohepatiitis. Phospholipidosis is a disruption of the phospholipidases activity, either by direct inhibition or through drug-phospholipid complexes that cannot be broken by them, leading to intracellular phospholipid accumulation. Although not a toxic event by itself, phospholipidosis predict drug and metabolite accumulation that may provoke toxicity within the liver or kidney for example. Drug induced steatosis and phospholipidosis can be quantified by High Content Screening.
Ask for high quality link by putting your email below
Ask for high quality link by putting your email below
View and download on Slideshare (low quality) : https://fr.slideshare.net/hcspharma/hepg2-cell-model-for-steatosis-and-phospholipidosis-assessment
2 Comments
Elrig » Event in BrusselsElrig · December 2, 2015 at 10:47 am
[…] disease and oncology and performed also really nice images showed in these other posters: hepatotoxicity assay and genotoxicity […]
Our feedback of Drug Discovery 2015 in Telford | HCS-pharma · March 16, 2017 at 10:09 am
[…] The first one was about the development of a neuroprotection assay as a Parkinson’s desease model in 2D culture. First results on 3D culture, where we can see the neurites connecting different spheroids, were also presented. The second poster showed the validation results of steatosis & phospholipidosis assay on HepG2 cells. […]